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Lung cancera b s t r a c t
Introduction: Local recurrence after lung SBRT for early stage NSCLC is rare but its treatment remains a
challenge due to limited surgical options. We report a case series of 5 patients treated by stereotactic lung
salvage reirradiation for local relapse after a previous lung SBRT.
Material and methods: Included patients presented an isolated primary lung relapse within at least the
50% isodose of the previous SBRT treatment. Typical reirradiation schedule was 60 Gy in 8 fractions at
isodose 80% and was delivered by Cyberknife using Synchrony fiducial tracking system. Dose summa-
tions were performed to evaluate the safety of the reirradiation.
Results: We identified 5 patients presenting peripheral lesions. All reirradiated lesions were locally con-
trolled after a median follow-up of 11.1 months (6,7–12,2), while PFS at 6 months was 60% (n = 3). We did
not notice any Grade 3 or more acute or late adverse event.
Conclusion: We observed encouraging short-term outcome of lung SBRT reirradiation in patients present-
ing isolated local relapse of an early-stage NSCLC. Further studies are necessary to confirm the safety and
efficiency of this salvage treatment approach.
 2021 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/
4.0/).Introduction
Stereotactic body radiotherapy (SBRT) is a well-established
treatment option for patients presenting an early-stage non-
small cell lung cancer (NSCLC). The main failure pattern after lung
SBRT is represented by distant failure. Local recurrence in a previ-
ously irradiated lung volume is observed in 5 to 15% of cases and
treatment remains a challenge due to co-morbidities limiting sur-
gical options [1]. Retreatment with conventional fractionated
radiotherapy (CFRT) can be consider as a salvage option but
remains poor outcomes [2]. Few studies explored salvage SBRT
for reirradiation after a first course of lung SBRT, more experiences
must be described to determine control and toxicity rates. We
recently considered the opportunity to repeat lung SBRT. Here
we report a case series of 5 patients treated by stereotactic lung
salvage reirradiation for local relapse after a previous lung SBRT.Material and methods
From November 2019, during our clinical follow-up, we identi-
fied patients who presented localized lung relapses in a previously
irradiated volume by SBRT. We included in this report patients pre-
senting an isolated primary lung relapse within at least the 50%
isodose of the previous SBRT treatment. The decision to reirradiate
was approved by the local multidisciplinary thoracic tumor board,
and patients were not considered eligible for salvage surgery due
to co-morbidities. All patients benefited from reirradiation after
fiducial marker (FM) placement and was performed by Cyberknife
using Synchrony fiducial tracking system (Accuray, Sunnyvale).
Typical reirradiation schedule was 60 Gy in 8 fractions at isodose
80% corresponding to a Biological Effective Dose for a/b 10 Gy
(BED10) of 105 Gy. We performed deformable registration on
Raystation (Raysearch, Stockholm) treatment planning system,
then plans were summed in order to evaluate the safety of the reir-
radiation treatment. Cumulative dosimetry had to respect the con-
straints of a 5 fractions plan for organs at risk according to
American Association of Physicists in Medicine doses constraints
[3]. Cumulative dosimetry had particularly to respect firstly spinal
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straints V5 < 65%,and finally both V12.5 < 1500 cc,V13.5 < 1000 cc.
There was no maximal dose limit in lungs while maximal dose had
to be localized in the PTV of the reirradiated target.Results
We identified 5 patients, 3 out of 5 relapses were histologically
proven, and the remaining two were assessed by their clinical evo-
lution followed by iterative morphological and metabolic imaging.
The median age of patients at relapse was 78.9 years (range,
62.6–88.8) and relapse was diagnosed with a median time lapse
of 31.3 months (range, 15.4–91.6) after the first SBRT. First SBRT
median dose was 55 Gy (45–60) in 5 fractions [3–8]. Most of first
lung cancers (4/5) were classified as cT1N0M0 (8th TNM classifica-
tion). The remaining last patient was firstly irradiated for an iso-
lated lung relapse of a lung adenocarcinoma previously
(20 months before the radiation therapy) treated by surgical
resection.
The mean lung dose (MLD) of the reirradiation was 1.9 Gy
(range, 1.0–2.0), the volume of lungs receiving 5 Gy (V5) was
7.5% (range, 4.9–9.5) and V20 1% (range, 0.8–3.9). All reirradiated
lesions were peripherally located and the median Planning Target
Volume (PTV) was 4.0 mL.
Three patients previously received Cyberknife treatment with
fiducial tracking, one patient had Tomotherapy SBRT, and one had
a VMAT SBRT treatment.
After reirradiation, cumulative MLD was 5.1 Gy (range, 3.6–7.8)
and cumulative V5 was 28.5 Gy (range, 16.0–48.5). Median maxi-
mal cumulated PTV dose was 90.8 Gy (range, 76.2–135.8) (Table 1).
All reirradiated lesions were locally controlled after a median
follow-up of 11.1 months (6,7–12,2), while PFS at 6 months was
60% (n = 3). One patient presented at 6 months a contralateral
new lung lesion successively treated by SBRT. Another patient
developed a single brain metastasis that was surged and irradiated.
We did not notice any Grade 3 or more acute or late adverse event
(Common Terminology Criteria for Adverse Events version 4) [4].
Most frequent adverse event was acute Grade 1 asthenia in 2
patients.Discussion
We report our early clinical outcome after lung SBRT reirradia-
tion. It may represents a new salvage option for these non-
operable patients with significant co-morbidities.
The singularity of our data is that we report a series of patients
who underwent two sequences of lung high-dose SBRT closely
located. Most of publications concerning SBRT reirradiation for
local relapse usually report data after a single or two
conventionally-fractionated course/s. These experiences revealed
acceptable local control rate with relatively high rates of lung tox-Table 1


















N-1 82,6 1 SCC 93,4 60/8 60/8
N-2 88,8 2 SCC 31,3 55/5 50/5
N-3 75,2 1 ADK 37,5 54/3 60/8
N-4 78,9 2 SCC 15,6 45/3 35/5
N-5 62,6 1 ADK 21,4 55/5 60/8
SCC: Squamous cell cancer.
ADK: Adenocarcinoma.
86icity such as radiation induced pneumonitis [5–9]. Synchrony
tracking system uses a 3-D co-ordinate system that tracks the tar-
get during the respiratory cycle by means of previously inserted
metallic FM. The tracking system permits the maximal reduction
of margins conducing to a better sparing of healthy lung tissue.
As reirradiation volume always correlates with toxicity outcome
in the reirradiation setting, our accurate SBRT technique permits
a better toxicity outcome. Moreover we choosed a fractionated reg-
imen in 8 fractions (usually used for ultra-central lesions) in order
to enhance tolerance of treatment while persevering biological
efficiency ((BED10) of 105 Gy).
Kennedy et al. also used accurate SBRT technique in a compara-
ble study population. Their experience represents the largest
cohort with 21 included patients. They remained a low rate of
Grade 2 lung toxicity (10% of pneumonitis) and no Grade 3 toxicity
while local control was 81% at 2 years.
John et al, recently published a retrospective multicenter (n = 8)
study focused on patients (n = 27) treated by two courses of lung
SBRT. The reported one-year local control rate was 78.3% and no
grade > 2 toxicity was observed. However, the reported delivered
doses were inferior to those of our series. In particular, the first
course median dose was 38.5 Gy in 5 fractions while the median
reported dose was 40 Gy in 5 fractions [10].
Hear et al reported a series of 10 patients that benefited of SBRT
reirradiation with BED10 doses  100 Gy, this treatment was con-
sidered as a viable salvage option for inoperable locally recurrent
NSCLC [11]. Nishimura et al also reported the cases of two elderly
patients successfully treated by salvage lung SBRT reirradiation
[12]. In our experience, we performed cumulative physical dose
summation to evaluate the safety of the reirradiation. Cumulative
dose had to respect the most restrictive constraints template for
stereotactic radiotherapy (Fig. 1). As an example, if the first course
was delivered in 5 fractions and the reirradiation was delivered in
8 fractions, the composite plan had to respect the constraints of a 5
fraction plan for organs at risk according to American Association
of Physicists in Medicine doses constraints [3]. Moreover, we col-
lected data concerning MLD and V5 and tried to optimize their val-
ues, as higher values seem to be part of complications occurrence,
and we did not observed any Grade 3 or more toxicity at last news
[13,14]. We can notice that we did not treat central or ultra-central
tumors directly invading bronchial tree [15]. The main limitation
of the report is the low number of patients, however our results
seems to correspond to the previously published data.Conclusion
In our preliminary experience, we observed short-term favor-
able outcome of lung SBRT reirradiation in patients presenting iso-
lated local relapse of an early-stage NSCLC. Further studies are
necessary in order to establish if this approach could be considered























135,3 1,6 7,3 7,5 32,0
90,3 1,9 5,1 7,3 28,5
90,8 1,1 4,1 4,9 16,0
76,2 2,0 7,8 9,0 48,5
101,1 2,0 3,6 9,5 19,0
Fig. 1. Dosimetric presentation of patient N-2. Left: current relapse treatment of 50 Gy in 5 fractions. Middle: previous SBRT irradiation dose of 55 Gy in 5 fractions registered
using deformable registration on current CT. Right: cumulative dosimetry of treatments with maximal point dose of 92.4 Gy.
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